Home

Daniel J. O'Connor

CIK 1376847 · President and CEO · last filed 2026-06-03

Daniel J. O'Connor is a President and CEO who has filed 88 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for DMAC, was dated Jun 3, 2026. Across all open-market trades the lifetime net is −$845.8K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

8

Total Filings

88

Lifetime Open-Market Net

-$845.8K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DMAC Director 0 $6.64 $0 $0 2 2026-06-03
Ambrx Biopharma, Inc. (AMAM) Delisted President and CEO 0 $28.00 $0 -$491.1K 5 2024-03-07
SEELOS THERAPEUTICS, INC. (SEEL) Delisted Director 4 $0.39 $2 $9.8K 7 2024-01-08
ZyVersa Therapeutics, Inc. (LSPRW) Delisted Chief Executive Officer 42,005 $0.18 $7.6K $0 1 2022-03-10
ONCOSEC MEDICAL Inc (ONCS) Delisted CEO and President 4,368 $0.28 $1.2K -$48.5K 18 2021-05-04
Ayala Pharmaceuticals, Inc. (ADXSW) Delisted Chief Executive Officer 618,352 — — -$68.6K 11 2017-07-03
Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted Chief Executive Officer 302,710 — — -$247.4K 39 2016-10-04
IMCLONE SYSTEMS INC (IMCL) Delisted SVP, Interim Gen. Counsel, Sec — — — $0 2 2007-02-21

Recent Filings

88 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-03 DMAC Grant (A) — $0 EDGAR
2025-02-24 DMAC Grant (A) — $0 EDGAR
2024-03-07 Ambrx Biopharma, Inc. (AMAM) Delisted Disp (D) −48,202 $0 EDGAR
2024-01-08 SEELOS THERAPEUTICS, INC. (SEEL) Delisted Grant (A) — $0 EDGAR
2023-12-11 Ambrx Biopharma, Inc. (AMAM) Delisted Grant (A) +750,000 $0 EDGAR
2023-11-01 — Notice (144) −50,012 -$491.2K EDGAR
2023-10-31 Ambrx Biopharma, Inc. (AMAM) Delisted Sell (S) −50,012 -$491.1K EDGAR
2023-07-07 Ambrx Biopharma, Inc. (AMAM) Delisted Grant (A) — $0 EDGAR
2023-04-28 Ambrx Biopharma, Inc. (AMAM) Delisted Grant (A) +2,750,000 $0 EDGAR
2023-01-05 SEELOS THERAPEUTICS, INC. (SEEL) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 88
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.